Amplify Weight Loss Drug & Treatment ETF THNR

Morningstar Medalist Rating

Morningstar’s Analysis THNR

Will THNR outperform in the future?

Get our overall rating based on a fundamental assessment of the pillars below.

null Morningstar Automated Analysis

Morningstar Automated Analysis

Summary

Amplify Weight Loss Drug & Treatment ETF holds a quantitatively derived Neutral Morningstar Medalist Rating. The rating suggests the model does not express a clear expectation of outperformance or underperformance relative to peers over a full market cycle.

Rated on Published on

Unlock our full analysis with Morningstar Investor

Portfolio Holdings THNR

  • Current Portfolio Date
  • Equity Holdings—
  • Bond Holdings—
  • Other Holdings—
  • % Assets in Top 10 Holdings67.0
Top 10 Holdings
% Portfolio Weight
Market Value USD
Sector

Eli Lilly and Co

12.10630,810
Healthcare

Novo Nordisk AS ADR

8.89463,717
Healthcare

Amgen Inc

6.11318,518
Healthcare

Regeneron Pharmaceuticals Inc

6.05315,305
Healthcare

AstraZeneca PLC

5.79302,129
Healthcare

Roche Holding AG Ordinary Shares new

5.68295,987
Healthcare

Gilead Sciences Inc

5.66295,148
Healthcare

AbbVie Inc

5.65294,440
Healthcare

Pfizer Inc

5.24273,184
Healthcare

Chugai Pharmaceutical Co Ltd

5.17269,506
Healthcare

Sponsor Center